Sotera Health (SHC) Stock Overview
Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
SHC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sotera Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.86 |
| 52 Week High | US$17.04 |
| 52 Week Low | US$9.53 |
| Beta | 1.82 |
| 1 Month Change | 7.46% |
| 3 Month Change | 37.07% |
| 1 Year Change | 9.55% |
| 3 Year Change | 143.64% |
| 5 Year Change | n/a |
| Change since IPO | -32.83% |
Recent News & Updates
Recent updates
After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar
Aug 13
These 4 Measures Indicate That Sotera Health (NASDAQ:SHC) Is Using Debt Extensively
Jul 17Is There An Opportunity With Sotera Health Company's (NASDAQ:SHC) 48% Undervaluation?
Jun 12Sotera Health Company's (NASDAQ:SHC) 28% Price Boost Is Out Of Tune With Revenues
May 13What Does Sotera Health Company's (NASDAQ:SHC) Share Price Indicate?
Apr 24Is Sotera Health (NASDAQ:SHC) A Risky Investment?
Mar 31There May Be Reason For Hope In Sotera Health's (NASDAQ:SHC) Disappointing Earnings
Mar 07Some Confidence Is Lacking In Sotera Health Company's (NASDAQ:SHC) P/S
Feb 26Why Sotera Health Company (NASDAQ:SHC) Could Be Worth Watching
Jan 06Here's Why Sotera Health (NASDAQ:SHC) Has A Meaningful Debt Burden
Dec 05
Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth
Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures.McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount
Feb 08Shareholder Returns
| SHC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 4.3% | 5.8% | 1.3% |
| 1Y | 9.6% | -0.7% | 16.7% |
Return vs Industry: SHC exceeded the US Life Sciences industry which returned -0.7% over the past year.
Return vs Market: SHC underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 8.0% |
| Life Sciences Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SHC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SHC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for the medical device, pharmaceutical, and food safety and advanced applications markets.
Sotera Health Company Fundamentals Summary
| SHC fundamental statistics | |
|---|---|
| Market cap | US$4.80b |
| Earnings (TTM) | US$23.96m |
| Revenue (TTM) | US$1.12b |
Is SHC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHC income statement (TTM) | |
|---|---|
| Revenue | US$1.12b |
| Cost of Revenue | US$500.09m |
| Gross Profit | US$624.44m |
| Other Expenses | US$600.48m |
| Earnings | US$23.96m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 04, 2025
| Earnings per share (EPS) | 0.084 |
| Gross Margin | 55.53% |
| Net Profit Margin | 2.13% |
| Debt/Equity Ratio | 434.2% |
How did SHC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/24 21:57 |
| End of Day Share Price | 2025/10/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sotera Health Company is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Patrick Donnelly | Citigroup Inc |